$38.1 Million is the total value of venBio Partners L.P.'s 3 reported holdings in Q4 2018. The portfolio turnover from Q3 2018 to Q4 2018 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q4 2018 | ||||||||
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Apellis Pharmaceuticals, Inc | 5 | Q4 2018 | 77.1% |
| Verona Pharma PLC | 5 | Q4 2018 | 22.2% |
| Menlo Therapeutics Inc. | 4 | Q4 2018 | 33.9% |
| Nabriva Therapeutics PLC | 3 | Q2 2018 | 12.6% |
View venBio Partners L.P.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2019-02-14 |
| 13F-HR | 2018-11-14 |
| 13F-HR | 2018-08-14 |
| 13F-HR | 2018-04-25 |
| 13F-HR | 2018-04-25 |
View venBio Partners L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.